• Oral galactose has no therapeutic potential on cognitive deficit in Tg2576 fAD model.
Introduction
Alzheimer's disease (AD) is the most common neurodegenerative disease associated with irreversible loss of neurons and progressive cognitive impairment (Nussbaum and Ellis, 2003) . Metabolic dysfunction is widely endorsed as an important feature of AD (Neth and Craft, 2017) , in particular brain insulin resistance which is closely tied to cognitive decline (Arvanitakis et al., 2004; De Felice et al., 2014; Talbot, 2014) . Additionally, decreased brain glucose metabolism has been found in AD patients expressed as characteristic and progressive reductions in fluorodeoxyglucose (FDG) positron emission tomography (PET) measurements of the regional cerebral metabolic rate for glucose (Langbaum et al., 2009) . Literature data indicates a link between AD and type 2 diabetes mellitus (T2DM), obesity and other prediabetic states of insulin resistance which have been associated with an increased risk of developing AD and related disorders (Arnold et al., 2018; Riederer et al., 2017) .
The vast majority of AD cases is of sporadic AD form (sAD), whereas the rare dominantly inherited familial form of the disease (fAD) arises from the mutation or duplication of the amyloid-β precursor protein (APP) gene, or from the mutation of the presenilin (PS) genes (Israel et al., 2012) . Reports on dysfunctional metabolic homeostasis centrally and/or peripherally, refer to the prevailing sAD form (Cai et al., 2012; de la Monte, 2014; Hoyer, 2004) , while metabolic characterization of fAD is lacking in patients and is modest in their animal counterparts, transgenic mice models developed to investigate AD pathophysiology. Contrary to the sAD animal models which are induced mostly by toxins, in particular by intracerebroventricular administration of the beta-cytotoxic compound streptozotocin (STZ-icv model) (De Felice et al., 2014; De La Monte and Tong, 2014; Osmanovic Barilar et al., 2015; Talbot et al., 2012) , transgenic models are obtained using various techniques of gene manipulations, most prominently through mutations of the APP (Platt et al., 2013) and PS1 and PS2 genes (Elder et al., 2010) . Manipulation with other Aβ-and tau protein or insulin-homeostasis-related genes as well as their multiple combinations have also been used as a platform to investigate AD pathophysiology (LaFerla and Green, 2012; Neha et al., 2014) . Tg2576 transgenic mice overexpress a mutant form of the human APP 695 (Hsiao et al., 1996) and show normal development, but exhibit age-associated cognitive deficits. There are papers showing that cognitive impairment in Tg2576 mice appears as early as 4 months (Jacobsen et al., 2006) or 6 months of age (Westerman et al., 2002) , but others report that cognitive impairment correlates with amyloid plaques and Aβ deposits starting at 9-10 months (Hsiao et al., 1996) , 11 months (Irizarry et al., 1997) , and 7-12 months (Ognibene et al., 2005) .
There are few data on brain insulin resistance and peripheral metabolic homeostasis in transgenic AD mice. Early alterations in genes involved in insulin and energy metabolism pathways were found in APP/PS1 transgenic mice at the age of 6 months before plaque detection, reinforcing the hypothesis that the impairments in both insulin signaling and energy metabolism precede the development of AD amyloidogenesis (Pedrós et al., 2014) . The 3xTg-AD transgenic mouse model demonstrated upregulation of several upstream components and downregulation of several downstream components of the insulin signaling pathway in the hippocampus (Chen et al., 2013) . Additionally, 14 month-old female 3xTg-AD mice displayed significant deterioration in glucose tolerance with fasting plasma insulin levels rising 2.5-fold from 6 to 14 month of age, while the changes were less pronounced in the males (Vandal et al., 2015) . A significant increase of glucose and decrease of insulin level, respectively, was detected in the brain of 12-month-old NSE/hPS2m transgenic mice . In the Tg2576 mice model, lower basal serum insulin concentrations and a delayed insulin-induced reduction in blood glucose levels relative to wild-type mice was determined in 8-month females (Pedersen and Flynn, 2004) , while the expression and activity of phosphofructokinase, one of the key enzymes of brain glycolysis, was found reduced in 24-but not in ≤17-month old Tg2576 mice (Bigl et al., 2003) .
Considering the failure in drug development clinical AD trials (Mangialasche et al., 2010) and based on the premise that sAD stems from brain glucose/insulin dysregulation, normalization of glucose/ insulin homeostasis has become a new therapeutic anti-AD strategy and drugs approved to treat T2DM have been under investigation for their therapeutic potential in clinical trials with AD patients (Gejl et al., 2016; Talbot and Wang, 2014; Yarchoan and Arnold, 2014) . Among them currently most explored are incretin-based drugs, the analogues of glucagon-like peptide 1 (GLP-1) and the inhibitors of the enzyme responsible for the rapid GLP-1 cleavage, dipeptidyl peptidase-4 (DPP4-I) (Bomfim et al., 2012; Calsolaro and Edison, 2015; Egefjord et al., 2012; Hölscher, 2014a; Kosaraju et al., 2013b Kosaraju et al., , 2013a Tai et al., 2018a) , since in addition to its incretin effect GLP-1 has shown a number of pleiotropic neuroprotective effects in animal models of neurodegenerative disorders including AD (Gupta, 2012; Holst et al., 2011; Salcedo et al., 2012) .
Our previous work has shown that chronic oral administration of galactose (a C-epimer of D-glucose) may have therapeutic potential in the STZ-icv rat model of sAD (Knezovic et al., 2018; Salkovic-Petrisic et al., 2014) . One-month treatment with 200 mg/kg/day of oral galactose successfully prevented STZ-induced learning and memory deficit when initiated immediately after STZ-icv administration (SalkovicPetrisic et al., 2014) and 2-month treatment with 200 mg/kg/day of oral galactose normalized already developed impaired learning and memory functions when initiated 1 month after STZ-icv administration (Knezovic et al., 2018) . Once absorbed, galactose may be converted into energy by entering the glycolytic pathway after its conversion to glucose-6-phosphate through the Leloir pathway (Frey, 1996; Petry and Reichardt, 1998) and thus restore STZ-induced reduction in brain energy metabolism. Alternatively, an indirect effect might be postulated through the mediation by glucagon-like peptide 1 (GLP-1) and its neuroprotective, neurotrophic, and neuroendocrine role; as demonstrated in our previous research by galactose-induced increments in plasma levels of active GLP-1 and increased expression of GLP-1 receptor in the hippocampus (GLP-1R) (Knezovic et al., 2018) .
Building on previous results (Knezovic et al., 2018; Salkovic-Petrisic et al., 2014) , this research aims to investigate whether oral galactose treatment elicits the same beneficial effect on cognitive deficits in an experimental model of fAD, represented by Tg2576 transgenic mice at 5 and 10 months of age at the initiation of therapy as well as in a mild-tomoderate sAD model using 7 month old rats (4 months after the STZ-icv treatment) at the time of initiation of 2 month oral galactose treatment. Additionally, we aimed to explore the metabolic homeostasis related to GLP-1 in this transgenic model and compare it with the one in the STZicv rat model of mild-to-moderate sAD.
Material and methods

Animals
Adult male B6; SJL-Tg(APPSWE)2576 Kha heterozygous transgenic mice (TG), corresponding wild types (WT) aged 5 and 10 months (Taconic Biosciences Inc., Hudson NY, USA) and adult (3-month old) male Wistar rats (University of Zagreb, School of Medicine, Department of Pharmacology) were used in the experiments. Mice were individually housed in cages with wood-chip bedding located in ventilated cabinets certifying constant temperature (22-24°C) and humidity (40-60%), situated in an air-conditioned room with a 12-h light/12-h dark cycle, specialized for housing of transgenic animals (Croatian Institute for Brain Research, University of Zagreb School of Medicine), while rats were housed in cages (2-3 rats per cage) located in the neighboring animal facility of the Department of Pharmacology, University of Zagreb School of Medicine. Animals were kept on standardized food pellets and water ad libitum. 
Drug treatments
Galactose treatment. D-galactose (GAL) was dissolved in tap water (200 mg/kg/day) and given as a drink ad libitum for 2 months. Mice received daily administration of 10 ml of GAL solution per individually caged mouse, corresponding to 0.06% galactose solution, with the required concentration adjusted weekly according to the mouse body weight), while rats received daily administration of 20 mL galactose solution per rat, corresponding to 0.3% galactose solution. Galactose treatment was performed during the separation of rats from their cagemates and individual caging on a daily basis from 1 p.m. to 8 a.m. next day as performed in our previous experiment (Knezovic et al., 2018) . Control mice and rats were given the same amount of tap water ad libitum as their respective AD counterparts. Streptozotocin (STZ) treatment. At 3 months, rats were subjected to general anesthesia (ketamine 50 mg/kg/xylazine 5 mg/kg ip) and given STZ-icv bilaterally into each lateral ventricle (2 μL/ventricle) in a total dose of 3 mg/kg (dissolved in 0.05 M citrate buffer, pH 4.5, split in two doses on day 1 and 3, with control animals receiving citric buffer only in the same manner), according to a well-established procedure repeatedly used in our previous research (Knezovic et al., 2018) .
Behavioral testing
Morris Water Maze (MWM) test. MWM was performed before (to assess cognitive baseline) and after GAL treatment (to assess the effect of the treatment) in both mice and rats. The test (Vorhees and Williams, 2006) consisted of a total of 6 trial days; 5 learning and memory trial days with 4 trials per day (each from a different starting point; Southwest (SW), South (S), East (E) and Northeast (NE), separated by 30 min of rest periods), and a probe trial on day 6. Using a 120 cm (mice) or 180 cm (rats) diameter round pool filled with water at a temperature of 25 ± 1°C, 60 cm deep, on days 1-5 animals were trained to escape water by finding a hidden, 15 cm diameter wide, glass platform submerged 2 cm below water surface. Each training day, the platform was placed at the edge of the Northwestern (NW) quadrant and animals were allowed to remain on the platform for 15 s to memorize its location. The time needed to find the platform after being released in the pool (i.e. escape latency) was recorded in every training trial to assess the aptitude of learning memory. On day 6, a probe trial was conducted to assess the animals' memory retention by releasing the mice/rats from the Southeastern (SE) quadrant with the platform removed from the pool. Time spent in search of the platform in the NW quadrant was recorded. In addition, non-target zone entries (entries to quadrants other than NW; i.e. "number of mistakes"), total distance moved and velocity were also recorded for all trials. Animals with memory impairment were expected to have diminished memory of the platform's location in the NW quadrant, and consequently, to spend less time in search of the platform within the quadrant. Data was acquired by Basler AG camera and tracked and analyzed by EthoVision XT software (Noldus Information Technology). Open field (OF) test. To assess anxiety-like behavior in mice OF was performed before and after GAL treatment in both mice experiments. The test was performed in a square chamber measuring 50 cm (length) x 50 cm (width) x 40 cm (height) positioned in a normally lit room, acquired by camera (Basler AG) and tracked and analyzed by video software (EthoVision XT by Noldus Information Technology). Mice movement within the chamber was recorded for 5 min, with grooming and rearing behavior manually recorded through the software. The tendency of an animal to remain in the areas close to walls of the chamber (thigmotaxis) was used as a measure of anxiety-like behavior, as thigmotaxis is deemed to increase as anxiety levels rise (Seibenhener and Wooten, 2015) . Each animal was placed in the same corner of the previously cleaned chamber and left to explore the chamber for 5 min. Elevated plus maze (EPM) test. EPM was performed before and after GAL treatment only in 10M mice (due to technical limitations) to assess the animals' anxiety response (Walf and Frye, 2007) . The test is performed in a plus-shaped Plexiglas apparatus elevated at a height of 50 cm, placed in a normally lit room. . Using a step-through type passive avoidance apparatus (Ugo Basile, Comerio, Italy) PA behavior was analyzed by exploiting the rodents' innate preference for dark environments (Ögren and Stiedl, 2013; Walters and Abel, 1971) . PAT is a fear-motivated avoidance task in which animals refrain from stepping through a sliding door to an apparently safer but previously punishment-related dark compartment. The latency to avoid stepping into the aversive compartment is used as an index of the ability to avoid, and allows evaluation of memory. The three-day PAT was performed after treatment with GAL. Day 1 was a habituation day to familiarize the animals with the environment (without foot shock, i.e. pre-shock latency), followed by a training day on day 2 in which a foot shock (0.3-0.5 mA, depending on the animal weight, duration 2 s) was conveyed, and, lastly, a testing day on day 3 (no foot shock, i.e. post-shock latency). The time required to enter the dark compartment was recorded with a cut-off time of 5 min. The PAT was performed at the end of the 2-month oral galactose treatment. Animals without memory impairment (controls) were expected to remember receiving the shock upon crossing into the dark compartment and, consequently, to remain in the light compartment for a longer period of time.
FDG-PET scan imaging
ClearPET high-performance small animal PET scanner was used. Performances of the commercial ClearPET scanner in terms of its spatial resolution, sensitivity and quality of phantoms and preclinical images were described by Roldan et al. (Sempere Roldan et al., 2007 FDG. After 30 min of uptake time, animals were anesthetized again as previously described and placed into the PET scanner. During the 30-min scanning (15 2-min frames), 2% isoflurane was delivered to animals by nose mask in order to maintain the anesthesia. No food was given to the animals between the two anesthesia. Obtained PET images were analyzed in PMOD software for biomedical analysis. For the brain analysis, the template of the animals' brain atlas available in PMOD software was used. Nine regions were selected as regions of interest for this study and underwent further analysis: 1) CTX frontal (orbito frontal, frontal, and medial prefrontal), 2) CTX parietal (parietal, cingulate, motor, retrosplenial, somatosensory and visual), 3) CTX temporal (auditory, entorhinal and insular), 4) Hippocampus, 5) Amygdala, 6) Hypothalamus, 7) Thalamus, 8) Brain Stem, and 9) Cerebellum. Results were given as 18 FDG activity per tissue volume [kBq/cc].
Intraperitoneal glucose tolerance test (ipGTT)
To assess the Tg2576 mice' glucose metabolism function, ipGTT was performed after GAL treatment in both mice experiments. The procedure (Ayala et al., 2010; Dinger et al., 2018) was conducted on overnight-fasted mice. Free-flowing blood was obtained by incising the animal's tail tip with sterile scissors. A 2 g/kg body weight glucose load (20% glucose solution in saline) was administered intraperitoneally. Blood glucose levels were measured using a glucometer and disposable test strips (Roche, Switzerland) before the load and 15, 30, 45, 60 and 120 min after the glucose load.
Biochemical analyses
Hippocampal homogenates preparation. Fresh frozen hippocampal tissue samples of mice and rats (N = 6 animals per group) were thawed and ultrasonically homogenized with lysis buffer (10 mM HEPES, 1 mM EDTA, 100 mM KCl, 1% Triton X-100, pH 7.5, with protease inhibitor cocktail (1:100) and PhosStop phosphatase inhibitor tablets (1:10)). The obtained homogenates were centrifuged at 12000 rpm (13700×g) for 10 min at 4°C and the supernatants frozen and stored at −80°C. Sample protein concentration was measured using the Lowry protein measurement assay (Lowry et al., 1951) . Western blot analysis. 25 μg (for mice) or 35 μg (for rats) of total hippocampal protein per sample were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis using 9% polyacrylamide gels, and transferred to nitrocellulose membranes. The membranes were blocked for 1 h at RT in a solution of 5% non-fat milk in low-salt washing buffer (LSWB) containing 10 mM Tris, 150 mM NaCl, pH 7.5 and 0.5% Tween 20. The blocked blots were incubated with primary antibody (anti-insulin receptor (β-Subunit), anti-phospho-GSK-3β, anti-β-tubulin, anti-SYP, anti-PSD-95, anti-GLP-1 receptor, anti-total GSK3 diluted 1:1000, anti-β-actin diluted 1:5000) overnight at 4°C. After incubation, the membranes were washed 3x with LSWB and incubated for 1 h at room temperature (RT) with the appropriate secondary antibody solution (anti-rabbit IgG or anti-mouse IgG, 1:2000). After 3x washing in LSWB, immunoreactivity was visualized using a chemiluminescence Western blotting detection reagent. The signals were captured and visualized with a MicroChemi video camera system (DNR Bio-Imaging Systems). The membranes were washed 3x with LSWB, blocked the same way, and incubated overnight with a loading control (anti-β-actin or anti-β-tubulin, 1:2000) at 4°C. The membranes were then washed and incubated for 1 h at RT with the appropriate secondary antibody solution (anti-rabbit IgG or anti-mouse IgG, 1:2000), washed in LSWB, and immunostained using a chemiluminescence reagent. The signals were captured and visualized with a MicroChemi video camera system. Soluble Aβ1-42 measurement. Soluble Aβ1-42 levels were measured in hippocampal homogenates using a commercial ELISA kit for human and rat amyloid beta peptide 1-42 (range: 12.35 pg/ml -1000 pg/ml; sensitivity: < 4.96 pg/ml). The procedure was done by precisely adhering to the manufacturer's protocol. Absorbance was measured at 450 nm using a microplate reader. The obtained concentration was expressed in pg/mL. Total GLP-1 measurement. Plasma levels of total GLP-1 (GLP-1 7-36 and 9-36) were measured using a commercial ELISA kit (sensitivity: 1.5 pM). The measurement was effected in accordance with the manufacturer's protocol. Absorbance was measured at 450 nm and 590 nm using a microplate reader. The concentration of total GLP-1 was expressed in pmol/L (pM). Active GLP-1 measurement. Active GLP-1 (GLP-1 7-36 and 7-37) levels in plasma samples were measured using a commercial ELISA kit (sensitivity: 2 pM). The measurement was performed with adherence to the manufacturer's protocol. The plate was read on a fluorescence plate reader at an excitation/emission wavelength of 355/460 nm. The concentration of active GLP-1 was expressed in pmol/L (pM). The GLP-1 active ELISA kit quantifies active forms of GLP-1 (7-36 amide and 7-37) and does not detect other forms, while the GLP-1 total ELISA kit is intended for quantification of both active (7−36) and non-active (9-36; degraded by dipeptidyl peptidase IV) forms. Insulin measurement. Plasma insulin levels were measured using a commercial insulin ELISA kit (sensitivity: 0.1 ng/ml). The procedure was done by precisely following the manufacturer's protocol. Absorbance was measured at 450 nm and 590 nm using a microplate reader. The concentration of insulin was expressed in ng/mL.
Experimental design
Two experiments on mice were conducted to assess the therapeutic potential and metabolic effects of galactose in two stages of a transgenic familial model of AD, presymptomatic and mild fAD. The first experiment to assess the effect of galactose in fAD was initiated at the animals' age of 5 months (4 groups, 9 animals per group further designated as 5M/before GAL/and 5M+2M/after GAL/, respectively), Initiation of the treatment at the age of 5 months was chosen as according to literature data on this model it is a life-time period before the appearance of cognitive deficit (Lesné et al., 2006) due to which it can be considered as presymptomatic fAD. In the second experiment, the effects of galactose in fAD were assessed after treatment initiation at the animals' age of 10 months (4 groups, 9 animals per group, further designated as 10M/before GAL/and 10M+2M/after GAL/, respectively). Initiation of the treatment at the age of 10 months was chosen as according to the literature data on this model it is a life-time period with already manifested mild cognitive deficit followed by mild neurochemical changes but prior to the appearance of plaque accumulation (Lesné et al., 2006; Oddo et al., 2006 ) (lack of plaques confirmed in our preliminary experiment, data not shown) and due to which it can been considered as mild fAD (Hsiao et al., 1996; Jacobsen et al., 2006) . This research has been primarily focused on the metabolic characterization of Tg2576 mice before and after GAL treatment but for comparison, we have additionally conducted an experiment using rats 4-months post-STZ-icv at the time of initiation of the 2-month GAL treatment to measure some of the cognitive, metabolic and neurochemical parameters in mild-tomoderate sAD (in line with previously published sAD staging in STZ-icv rat model ). The rats were 9-month old at the time of these measurements. At the beginning of both mice experiments, before initiating oral GAL treatment (200 mg/kg/day), animals underwent MWM to assess their cognitive baseline. GAL solution was given as a drink ad libitum for 2-months and metabolic, behavioral and cognitive testing was performed within the last 10-12 days of this treatment period. The testing in mice started with ipGTT (after overnight food deprivation), continued with OF and EPM (each 1 day, EPM performed only in 10M+2M mice) and then followed by MWM (6 days). Two (5M+2M) and 4 (10M+2M) mice per group, respectively, underwent FDG-PET scanning the next day. In the experiment done on rats, animals were divided into 4 groups (10 animals per group); control group (vehicle-icv treated; CTR), STZ-icv group (STZ), control group treated daily with GAL 200 mg/kg p.o. (CTR + GAL), and STZ-icv group treated daily with GAL 200 mg/kg p.o. (STZ + GAL). In rats, cognitive performance assessed by MWM was done before and after GAL treatment while PAT and FDG-PET scanning (2 rats per group) were performed after 2-months of oral galactose treatment in the same way and as in mice experiments. The last day of MWM probe trial was the first day of PAT which lasted in total 3 days and the rats underwent FDG-PET scanning the next day. In all experiments, both mice and rats were sacrificed the day after FDG-PET, when FDG was eliminated from the body. Animal blood samples for ELISA measurements were taken before sacrificing the animals. Mice and rats were euthanized in general anesthesia (thiopental 60 mg/kg/diazepam 6 mg/kg ip) followed by decapitation; the brains were quickly removed on ice, and the hippocampus dissected out, frozen in liquid nitrogen, and stored at −80°C. The research was primarily focused on Tg2576 mice while STZ-icv rats were used for comparison of some of the key parameters.
Ethics
All animal procedures were carried out in compliance with current institutional (University of Zagreb School of Medicine), national (Animal Protection Act, NN 102/17) and international (Directive, 2010/63/EU) guidelines on the use of experimental animals. The experiments were also approved by the national regulatory body, the Croatian Ministry of Agriculture (license number 525-10/0255-15-5 for the same project which included experiments in both mice and rats).
Statistics
Data were expressed as mean ± SEM. Significance of betweengroup differences in all cognitive and biochemical analyses was tested using Kruskal-Wallis (KW) one-way analysis of variance, followed by Mann-Whitney U test. Longitudinal data were analyzed by two-way repeated measures ANOVA (RM ANOVA) with Bonferroni posttests, with p < 0.05 considered as statistically significant. Data was analyzed using GraphPad Prism 5 statistical software.
Theory
Transgenic mice AD models are the most exploited experimental models in AD research despite the fact that they generally represent the rare fAD form, while > 95% patients with AD suffer from late-onset sAD. In order to better mimic the human disease, the initial brain pathology in fAD and sAD animal models is generated via completely different mechanisms, i.e. by manipulation of APP-and/or PS1-and tau-genes, and by central administration of neurotoxic agents, respectively (Götz and Ittner, 2008; Neha et al., 2014) . Therefore, apart from the cognitive deficits, it is to be expected that underlying pathology, including metabolic alteration, and consequently the response to therapy based on normalization of metabolic imbalance, might differ between fAD and sAD animal models, the latter represented by STZ-icv rat or mice models. The studies of Chen and coworkers who explored 84 AD-related genes in STZ-icv mice and 3xTg AD mice (Y. Chen et al., 2012b ) support this assumption. They have found the altered expressions of around 20 genes in both mouse models, but the genes related to synaptic function were dysregulated in the 3xTg AD mice, whereas more genes related to insulin signaling and glucose metabolism were down-regulated in the STZ-icv mice (Y. Chen et al., 2012b) .
Based on that hypothesis, and our previous research in STZ-icv rat model pointing to the altered homeostasis of GLP-1 in plasma in early sAD stage, and capability of oral galactose to improve it (Knezovic et al., 2018) , we have hypothesized that transgenic model of fAD might have different response to oral galactose treatment. The preclinical studies of GLP-1 agonists showed mostly positive results in transgenic mice fAD models (Cai et al., 2018; Cao et al., 2018; Chen et al., 2017; Long-Smith et al., 2013; McClean et al., 2015; McClean and Holscher, 2014; McClean and Hölscher, 2014; Tai et al., 2018b) and STZ-icv rat model of sAD (S. Chen et al., 2012a; Li et al., 2012; Shi et al., 2017; Solmaz et al., 2015) , but there are also reports of a possible inefficiency of incretin-based drugs in AD models (Bomba et al., 2013) . Therefore, it is necessary to characterize in depth and compare the incretin-related metabolic profile in fAD and sAD animal models. Additionally, due to its multi-target activity, oral galactose treatment might provide an additional value and different approach to the incretin-based therapy (Salkovic-Petrisic, 2018), and detailed characterization of the models used as a platform for the assessment of its therapeutic potential and possible limitations is the first step in this research.
Results
Body weight (mice)
Mice were weighed before, during and after GAL treatment. TG mice weighed significantly less than WT mice in both experiments, before (−15% in 5M, p < 0.0001; −26% in 10M, p < 0.0001; Table 1 ) and after (−15% in 5M+2M, p < 0.001; −15% in 10M +2M, p = 0.06; Table 1) GAL treatment, whereas GAL treatment did not affect the mice weight (Table 1) .
Cognitive performance (mice)
MWM baseline cognitive assessment. Before initializing GAL treatment, mice underwent MWM to assess their cognitive baseline. There was no significant difference in the number of mistakes (i.e., the number of entries into quadrants other than NW where the platform had been located) made between the 5M WT and TG groups during the 5 training days (Fig. 1a) , while TG animals spent significantly less time (−53%, p < 0.05) in search of the platform in the designated quadrant on day 6 (probe trial) (Fig. 1b) . 10M TG animals made more mistakes during the 5 training days compared to respective WT animals (with statistical significance on days 2 and 5, p < 0.05; Fig. 1a ) and showed a high tendency to spend less time in search of the platform in the correct quadrant on day 6 (−44%, p = 0.06; Fig. 1b) . MWM after GAL Table 1 Mice body weights measured before and after the 2-month long GAL treatment.
WT (mean ± SEM) N = 9 TG (mean ± SEM) N = 9 Difference (%) WT + GAL (mean ± SEM) N = 9 TG + GAL (mean ± SEM) N = 9 Difference (%) Mice were 5-(5M) and 10-(10M) month old at the time of initiation of GAL treatment that lasted for 2 months (5M+2M; 10M+2M). Body weight is expressed in grams. WT = wild-type, TG = transgenic Tg2576, WT + GAL = WT treated with oral galactose, TG + GAL = TG treated with oral galactose. Data were analyzed using non-parametric Kruskal-Wallis test followed by a Mann Whitney U test (*p < 0.05; **p < 0.01; ***p < 0.001).
treatment. After the 2-month-long treatment with oral GAL, 5M+2M animals showed no difference in cognitive performance between groups as shown by both time spent in search of the platform in the designated quadrant in the probe trial (KW test; p = 0.72) and the number of mistakes during the training trials (two-way RM ANOVA test; row factor p < 0.0001; column factor p = 0.56) (Fig. 1c and d) . 10M+2M
TG mice showed significant cognitive impairment compared to 10M +2M WT mice (KW test; p = 0.14) as shown by time spent in search of the platform (−75%, p < 0.05); however, there was no statistically significant improvement in cognition in the TG groups treated with GAL (two-way RM ANOVA test; row factor p < 0.0001; column factor p = 0.62) (Fig. 1c and d) . In comparison to the untreated group, (caption on next page) A. Babic Perhoc et al. Neuropharmacology 148 (2019) 50-67 galactose treatment in 10M+2M WT + GAL mice showed a tendency (p = 0.09) to negatively affect the cognition as seen in the MWM probe trial (Fig. 1d) . The animals' swimming patterns were analyzed by group heatmap images, which showed that TG animals displayed diminished activity in the MWM swimming pool compared to WT animals in both age groups (Fig. 2) . Oral galactose treatment tended to decrease the swimming activity in 10M+2M TG mice (Fig. 2.) , although significance was not reached due to the intragroup variability (Supplement 1, Fig. 1 ).
Anxiety behavior (mice)
TG animals spent less time grooming in the OF test compared to WT (5M+2M KW test p = 0.04; −95%, p < 0.01 for 5M+2M WT vs. 5M +2M TG; 10M+2M KW test p = 0.44; −34%, p = 0.13 for 10M+2M WT vs. 10M+2M TG; −68%, p < 0.01 for 10M+2M WT vs. 10M +2M TG + GAL) (Fig. 3) . However, there was no difference in open field time spent in center or total distance moved between groups in either experiment, possibly due to a large intragroup variability (Supplement 1, Fig. 2 ). Before GAL treatment, 10M TG animals spent more time in open arms in EPM test (+101%; p < 0.01) than the WT group (Fig. 4a) , demonstrating a pattern of behavior which has been suggested to reflect anti-anxiety behavior (Walf and Frye, 2007) . GAL treatment did not affect this behavior, as shown by time spent in open arms (KW test; p = 0.003) and number of entries to open arms (KW test; p = 0.01) (Fig. 4b) .
Glucose metabolism in the brain (mice)
In 5M+2M, PET scans demonstrated increased (+20%) glucose uptake/metabolism in the whole brain of TG mice compared to WT mice, which was normalized by galactose (decreased −14% 5M+2M TG + GAL mice; Fig. 5, Supplement 1) . In 10M+2M, PET scans showed decreased (−18%) glucose uptake/metabolism in the whole brain of TG mice compared to WT mice, which were normalized by galactose (increased +32% in 10M+2M TG + GAL mice, Fig. 5, Supplement 1) .
Glucose tolerance (mice)
In GAL-untreated WT and TG animals, the TG group showed impaired glucose tolerance (compared to the WT) in ipGTT only in the 10M+2M mice experiment (two-way RM ANOVA test: row factor p < 0.0001; column factor p = 0.0001) where glucose level increased +16 to +72% in different time points (Fig. 6 ) which was further worsened by galactose treatment in 10M+2M TG + GAL group (additional +21 to +51% increment, p < 0.05; Fig. 6 ). Galactose treatment had no effects in the 10M+2M WT group but lowered glucose levels in 5M+2M WT group (−32 to −45%, p < 0.05 for 5M +2M WT vs. 5M+2M WT + GAL; two-way RM ANOVA test: row factor p < 0.0001; column factor p = 0.04; Fig. 6 ).
Plasma GLP-1 measurements (mice)
The active-to-total GLP-1 ratio showed a pronounced tendency to decrease (p = 0.20) in the TG compared to the WT group only in 5M +2M (Fig. 7a) . Galactose treatment tended to decrease this ratio (p = 0.12) in the WT group but had no effects in TG mice (Fig. 7a) . Due to high intragroup variability in the WT group, the differences between the groups did not reach the significance level for 5M+2M (KW test; p = 0.25). In 10M+2M mice experiment, oral galactose showed a similar tendency of active-to-total GLP-1 ratio decrease in the WT group (p = 0.06 for WT + GAL vs WT) and had no effects in the TG + GAL vs TG group (KW test; p = 0.34). The active and total plasma GLP-1 values were not significantly changed between the groups in both experiments (Supplement 1, Fig. 3) . 
Plasma insulin measurement (mice)
In 5M+2M mice experiment, insulin levels were decreased in TG animals compared to WT (−50%, p < 0.05), which were significantly increased by GAL treatment (+222%, p < 0.05) (KW test; p = 0.02). On the other hand, in 10M+2M mice experiment, GAL significantly decreased insulin levels in TG animals compared to WT only (−56%, p < 0.05) but showed insignificant tendency to further decrease insulin levels in TG animals (p = 0.09). However, in WT mice GAL treatment tended to alter the plasma insulin levels in opposite directions; increase in 5M+2M mice (KW test p = 0.07) and decrease in 10M+2M mice (KW test; p = 0.06), respectively (Fig. 7b) .
Hippocampal Aβ1-42 measurement (mice)
Soluble Aβ levels were markedly increased in 5M+2M TG animals (+52% compared to WT, p < 0.05), which was further exacerbated by GAL treatment (+94% compared to WT, p < 0.01) (KW test; p = 0.008). In the 10M+2M experiment, TG animals had comparable Aβ levels to WT; however, GAL treatment markedly increased Aβ levels in the TG animals compared to WT (+59%, p < 0.05 for TG + GAL vs WT) and showed a high tendency to increase them compared to untreated TG group (46%, p = 0.06) (KW test; p = 0.07) (Fig. 7c) .
Western blot measurements of GLP-1R, IR, GSK3β, SYP and PSD-95 protein expression in the hippocampus (mice)
GLP-1R. There were no differences between the groups in the expression of GLP-1R in the hippocampi of 5M+2M animals (KW test; p = 0.92), whereas the expression of the receptor was significantly increased by GAL treatment in both 10M+2M transgenic and control mice (+116% compared to WT, p < 0.05; +170% compared to TG, p < 0.01; Fig. 8a ) (KW test; p = 0.001). IR. No differences in expression of IR was noted between the groups in 5M+2M (KW test; p = 0.61), while GAL treatment significantly decreased the expression of the receptor in 10M+2M TG animals (−39%, p < 0.05; Fig. 8b) 
Fig. 3. Tg2576 mice spend less time grooming during the Open Field test.
For the 5-and 10-month old mice groups, each bar represents mean ± SEM of the cumulative time (s) spent grooming during the 5-min long OF testing period conducted at the end of the 2-month oral galactose (200 mg/kg/day) treatment (5M+2M; 10M+2M). Data were analyzed by non-parametric Kruskal-Wallis test followed by a Mann Whitney U test (*p < 0.05; **p < 0.01) N = 9 animals per group. WT = wild-type, TG = transgenic Tg2576, WT + GAL = WT treated with oral galactose, TG + GAL = TG treated with oral galactose. (KW test; p = 0.06). GSK3β. The ratio of expression of phosphorylated/ total GSK3β was used as an indirect measure of GSK3β activity. Oral GAL treatment increased the p/t GSK3β ratio (+60% TG vs. TG + GAL, p < 0.0.1; Fig. 8c ), i.e. decreased the enzyme activity in 5M+2M animals (KW test; p = 0.02), but decreased it (−49% TG vs. TG + GAL, p < 0.05; Fig. 8c ), i.e. increased the enzyme activity in 10M+2M (KW test; p = 0.12). The values of the total and the phosphorylated GSK3β are presented in Supplement 1/ Fig. 4a and b. SYP. There was no Fig. 5 . Glucose uptake using FDG as a radiotracer in Tg2576 animals subjected to chronic oral galactose treatment. Regions of interest were selected and analyzed by PMOD software for indication of glucose uptake/metabolism rate. The bars represent calculated kBq/cc for each region and total brain. N = 2 animals per group in 5-month old mice subjected to 2-month oral galactose treatment (5M+2M) and 4 animals per group in 10-month old mice subjected to 2-month oral galactose treatment (10M+2M). WT = wild-type, TG = transgenic Tg2576, WT + GAL = WT treated with oral galactose, TG + GAL = TG treated with oral galactose; CTX = cortex, HPC = hippocampus, HPT = hypothalamus, OFB = olfactory bulb. Fig. 6 . Intraperitoneal glucose tolerance test shows beneficial effect of galactose on glucose metabolism in younger wild-type animals and impaired glucose metabolism of age-matched Tg2576 animals further worsened by oral galactose treatment in older Tg2576 mice. Mice were 5-(5M) and 10-(10M) month old at the time of initiation of GAL treatment that lasted for 2 months (5M+2M; 10M+2M). Each dot represents a group value (glucose concentration) expressed as mean. Data were analyzed by two-way RM ANOVA with Bonferroni post-hoc test. N = 9 animals per group. *p < 0.05 compared to WT + GAL; $p < 0.05 compared to WT; #p < 0.05 compared to TG. WT = wild-type, TG = transgenic Tg2576, WT + GAL = WT treated with oral galactose, TG + GAL = TG treated with oral galactose. difference in the hippocampal expression of SYP between any of the groups (KW test; p = 0.41 for 5M+2M; p = 0.49 for 10M+2M) (Fig. 8d) indicating both preserved integrity of the presynaptic terminal and inability of oral galactose to affect it in both wild-type and transgenic mice. PSD-95. The expression of PSD-95 as a measure of postsynaptic density was significantly increased in younger (5M+2M) TG mice compared to WT (+44%, p < 0.05) (KW test; p = 0.01), while no difference was noted in older mice (10M+2M) (KW test; p = 0.29). Oral galactose treatment increased the expression of PSD-95 in younger (5M+2M) WT + GAL mice (+93%, p < 0.01) compared to WT mice, while it had no effect in TG mice (Fig. 8e) . All Western blot images are presented in Supplement 3.
4.10. Cognitive, metabolic and neurochemical effects of oral galactose in a STZ-icv rat model of mild-to-moderate sAD Cognition. Galactose treatment did not elicit any improvements of STZ-icv-induced cognitive deficits in spatial memory measured by number of mistakes (i.e. non-target entries to quadrants other than NW) in MWM training trial days (two-way RM ANOVA test; row factor p < 0.0001; column factor p = 0.005) (Fig. 9a) and in the fear-motivated memory measured in PAT test (KW test; p = 0.0002) (Fig. 9a) .
However, it also did not deteriorate the cognition either in the STZ group or in the control rats (Fig. 9a) . FDG-PET scan. PET scans showed decreased (−12%) glucose uptake/metabolism in the whole brain of STZ rats compared to CTR, which was normalized by galactose (increased +38% in STZ + GAL vs STZ rats) rising to the levels above the controls (Fig. 9b, Supplement 1) . Plasma GLP-1. No differences were found between the groups in active and total GLP-1 plasma levels (active GLP-1 KW test p = 0.66; total GLP-1 KW test p = 0.33); however, a near statistically significant tendency to increase the active-to-total GLP-1 ratio was noted in STZ and particularly in STZ + GAL group (p = 0.06) compared to the CTR, respectively (KW test; p = 0.18) (Fig. 9c) . Plasma insulin. There were no statistically significant differences in plasma insulin level between any tested groups although CTR + GAL group tended to have decreased plasma insulin levels compared to the CTR (KW test; p = 0.27) (Fig. 9c) . Soluble Aβ1-42 in HPC. Soluble Aβ1-42 was increased in STZ animals (+87%, p < 0.01) which was decreased by GAL treatment with near statistical significance (−37%, p = 0.06) (KW test; p = 0.03) (Fig. 9c) . IR in HPC. The expression of hippocampal IR was increased in the STZ group (+41%, p < 0.05) and STZ + GAL group (+58%, p < 0.05) compared to the CTR (KW test; p = 0.02) (Fig. 9c) . pGSK3β/tGSK3 ratio in HPC. The pGSK3β/tGSK3 ratio showed a high tendency of increase in Fig. 7 . Oral galactose treatment decreases active-tototal GLP-1 ratio in wild-type animals; increases soluble Aβ1-42 levels in the hippocampus of both younger and older Tg2576 animals; and increases insulin plasma levels in younger, but decreases it in older Tg2576 animals. Mice were 5-(5M) and 10-(10M) month old at the time of initiation of GAL treatment that lasted for 2 months (5M+2M; 10M +2M). Each bar represents mean ± SEM of plasma/ hippocampal levels from samples obtained before sacrifice, after the 2-month oral galactose treatment (200 mg/kg/day) of a) active-to-total GLP-1 ratio (N = 9 animals per group), b) insulin (N = 9 animals per group) and c) soluble amyloid β1-42 (N = 6 animals per group). Data were analyzed by nonparametric Kruskal-Wallis test followed by a Mann Whitney U test (*p < 0.05; **p < 0.01). WT = wild-type, TG = transgenic Tg2576, WT + GAL = WT treated with oral galactose, TG + GAL = TG treated with oral galactose.
STZ animals (+105%, p = 0.08) indirectly indicating decreased GSK3β activity, and GAL treatment had no effects on STZ rats but significantly increased the ratio in the controls (+170%, p < 0.05 for CTRL + GAL vs CTRL; KW test; p = 0.10) (Fig. 9c) . GLP-1R in HPC. While STZ rats tended to have increased GLP-1R levels in comparison to the controls, GAL treatment decreased hippocampal content of GLP-1R in STZ animals without affecting the one in the controls (KW test; p = 0.18) (−38%, p < 0.05; Fig. 9c ). All Western blot images are presented in Supplement 3.
Discussion
The research presented here has provided the characterization of cognitive and behavioral impairments and associated alterations in the Fig. 8 . Western blot measurement of hippocampal GLP-1 receptor and insulin receptor protein expression and the GSK3β protein expression presented as the ratio of phosphorylated/total GSK3β. Mice were 5-(5M) and 10-(10M) month old at the time of initiation of GAL treatment that lasted for 2 months (5M+2M; 10M+2M). Each bar represents mean ± SEM of hippocampal expression of a) GLP-1 receptor; b) insulin receptor; c) phosphorylated-to-total GSK3β ratio; d) synaptophysin; e) postsynaptic density marker 95. Data were analyzed by non-parametric Kruskal-Wallis test followed by a Mann Whitney U test (*p < 0.05; **p < 0.01). N = 6 animals per group. WT = wild-type, TG = transgenic Tg2576, WT + GAL = WT treated with oral galactose, TG + GAL = TG treated with oral galactose.
central and peripheral glucose and insulin-related system as well as GLP-1 homeostasis in the transgenic Tg2576 mice as a model of fAD and their comparison with those found in STZ-icv rat model of mild-tomoderate sAD.
In our experiments transgenic Tg2576 mice showed impairments in anxiety behavior before the cognitive ones and oral galactose treatment demonstrated a clear tendency to increase the grooming behavior in 5M +2M transgenic, and also partly in the age-matched wild-type controls. However, it had no effects on the disinhibitory behavior in EPM test, suggested in the literature (Lassalle et al., 2008; Ognibene et al., 2005) as a possible reason for more active and less anxious behavior of Tg2576 mice compered to their wild-type controls (Deacon et al., 2009;  (caption on next page) A. Babic Perhoc et al. Neuropharmacology 148 (2019) 50-67 King and Arendash, 2002) . In contrast to the therapeutic effects seen as prevention and normalization of cognitive deficits in the early stage of STZ-icv rat model of sAD (Knezovic et al., 2018; Salkovic-Petrisic et al., 2014) , the presented results of the MWM test demonstrate that 2-month oral administration of GAL (200 mg/kg/day as a drink ad libitum) has no therapeutic potential on cognitive impairment in the transgenic Tg2576 mice model of fAD when initiated in 5-and 10-month old animals. It may be speculated that the beneficial effects of oral galactose treatment depend on the specific underlying pathology, present in the STZ-icv-sAD model but absent in the transgenic fAD model (Moreno et al., 2018; Y. Chen et al., 2012b) . This is in line with the mechanism of STZ-icv action which targets the brain insulin system and the signaling of IR consequently inducing the insulin-resistant brain state (Kamat et al., 2016; Shonesy et al., 2012) . Furthermore, the therapeutic effects of oral galactose on cognitive deficits seem to be dependent on the stage and/or severity of the AD-like pathology, since the cognitive improvement was previously seen in the early (Knezovic et al., 2018) but not here in the advanced stage of sAD (Fig. 9a) . Insulin resistant brain state (IRBS) is considered to be the pathophysiological core of the prevailing sporadic form of AD (Chen et al., 2014a; Correia et al., 2011; De Felice et al., 2014; De La Monte and Tong, 2014) and therefore, the STZ-icv model which is based on the induction of IRBS (Agrawal et al., 2011; Chen et al., 2014b; Osmanovic Barilar et al., 2015) and eventually develops cognitive deficits and AD-like neuropathology , has been recognized as a representative model of sAD (Kamat et al., 2016; Kraska et al., 2012) . STZ-icv rat model is the best characterized considering the staging of the AD-like pathology appearance, development and progression Osmanovic Barilar et al., 2015) . Cognitive deficits and underlying neurochemical alterations in STZ-icv rat model demonstrate acute, partially reversible reaction in the early post-STZ period (around 1 month) which then turns to the normal values at > 1-3 months, and after a critical time-point around 3 months post STZ slowly progressive and irreversible deterioration of cognitive loss and apparent pathological tau/Aβ accumulation starts to develop in the course of time . It might be speculated that in the STZ-icv rats used here (2-month galactose treatment initiated 4 months after STZ-icv treatment), irreversible AD-like neuropathology prevented the therapeutic effects of oral galactose, in contrast to its beneficial effects observed in STZ-icv rats in which galactose treatment was initiated 1 month after STZ administration (Knezovic et al., 2018) . One cannot exclude that, to a certain extent in some of the parameters presented here, similar AD stage-dependency in response to oral galactose exists also in the transgenic Tg2576 AD mice, which, due to the differences in the underlying pathology between the genetically modified and streptozotocin-induced AD models (Moreno et al., 2018; Y. Chen et al., 2012b) , might be less pronounced in Tg2576 mice.
The results presented here further indicate that in the absence of neurodegenerative pathology (i.e. in wild-type 10M+2M mice at the age of 12 months), oral galactose might have harmful effects on cognition, which has not been observed in the control (healthy) rats up to the age of 9 months (Knezovic et al., 2018; Salkovic-Petrisic et al., 2014) (Fig. 9a) . It seems likely that the effects of oral galactose can be manifested as toxic in physiological condition when there is no underlying pathology where galactose-providing energy supply would be required, like in healthy adolescent animals, or that it might aggravate aging-related pathology when given to older animals. Galactose dose/exposure probably plays a role in turning the effects to be harmful since at high levels galactose reacts with the free amines of amino acids in proteins and peptides and consequently forms advanced glycation end products which cause oxidative damage in the body (Shwe et al., 2018) . This galactose-induced effects have been used to model age-related development of brain oxidative stress and cognitive impairment induced by chronic exposure of healthy mice or rats to parenteral (intraperitoneal or subcutaneous) galactose in doses up to 500 mg/kg/day as extensively reviewed elsewhere (Shwe et al., 2018) . These doses are overlapping and are even higher with the oral galactose doses which showed beneficial cognitive effects in our previous research (100-300 mg/kg/day (Knezovic et al., 2018; Salkovic-Petrisic et al., 2014) . Therefore, considering an extensive first-pass hepatic clearance of oral galactose, different cerebral effects of the same galactose dose administered orally and parenterally might result from a higher final concentration of galactose reaching the brain following the parenteral administration as demonstrated in our previous research (SalkovicPetrisic et al., 2014) . In rats treated with a diet containing a different amount of galactose, a diet with low galactose content (15%) improved hepatic insulin sensitivity, while the one highly rich in galactose (> 30%) induced hypergalactosemia and symptoms of diabetes (Stahel et al., 2017) , which further supports the importance of the galactose dose. However, the treatment duration might also play a role as suggested by Chogtu and coworkers (Chogtu et al., 2018) who reported that acute beneficial effects of oral galactose (200 mg/kg/day) in healthy rats could be nullified or turned to harmful in a long-term treatment (seen after 8 weeks). The effects of oral galactose treatments > 2 months in sAD models remain to be explored.
Several possible mechanisms of oral galactose activity in Tg2576 mice were explored here and compared with those in STZ-icv rats.
Effects on the plasma level of GLP-1 and expression of GLP-1 receptors in the brain. In contrast to the parenteral application, oral administration of galactose is associated with a rise in plasma active GLP-1 levels and increased expression of GLP-1 receptors in the rat brain (Knezovic et al., 2018) . Considering the beneficial pleiotropic effects of GLP-1 manifested as neuroprotective, neurotrophic and neurogenesis-promoting activity (Figueiredo et al., 2010; Hölscher, 2014b) , such galactose-induced stimulation of the effects mediated by endogenous active GLP-1, might be reflected upon the improvement in cognitive deficits. Neither brain's nor plasma GLP-1 levels have been measured yet in any transgenic mice AD model, while the expression of GLP-1R in the brain was measured only in 15-18-month old APP/PS1 transgenic mice and was found comparable to that of the age-matched wild types (Denver et al., 2018) . There is no similar literature data on Tg2576 mice model for comparison with the GLP-1/GLP-1R results obtained here while there is only one report of other researcher demonstrating unaltered GLP-1 levels in the rat hippocampus 3 months following the STZ-icv treatment (Kosaraju et al., 2013b) . The ratio of active-to-total plasma GLP-1 values in the research presented here (Fig. 7a) indicates that the activity of this hormone tends to be decreased in fAD but much more in the presymptomatic than in the mild fAD stage (5M+2M vs Fig. 9 . In STZ-icv rats with mild-to-moderate sAD, chronic oral galactose normalizes glucose hypometabolism in the brain and has some beneficial metabolic and neurochemical effects but does not improve the cognition. Cognitive performance was measured in 9-month old rats at the end of the 2-month oral galactose treatment (200 mg/kg/day) which was initiated 4 months after the streptozotocin-intracerebroventricular injection. (a) Each dot represents a group value (number of mistakes; N = 10 animals per group) expressed as mean ± SEM of learning trials (days 1-5) in Morris Water Maze (MWM) test. Data were analyzed by two-way RM with Bonferroni post-hoc test. (b) Each bar represents mean ± SEM of latency time in the Passive Avoidance Test (PAT) (N = 10). Data were analyzed by nonparametric Kruskal-Wallis test followed by a Mann Whitney U test (*p < 0.05, **p < 0.01). (c) Regions of interest were selected and analyzed by PMOD software for indication of glucose uptake/metabolism rate. The bars represent calculated kBq/cc for each region and total brain. N = 2. (d) Each bar represents mean ± SEM of levels of plasma active-to-total glucagon-like peptide 1 (GLP-1; N = 10); plasma insulin (N = 10); hippocampal amyloid beta (Aβ1-42; N = 6); insulin receptor (IR; N = 6); phosphorylated-to-total glycogen synthase kinase 3 β (GSK3β; N = 6) ratio; glucagon-like peptide 1 receptor (GLP-1R; N = 6). Data were analyzed by non-parametric Kruskal-Wallis test followed by a Mann Whitney U test (*p < 0.05). CTR = controls, STZ=STZ-icv treated animals, CTR + GAL = CTR treated with 2-month oral galactose, STZ + GAL = STZ-icv treated with oral galactose.
10M+2M transgenic mice) and that oral galactose decreases this ratio in the WT mice but has not much effect in the transgenic ones. This suggests that the regulation of long-term oral galactose-induced increase in the endogenous GLP-1 might be disturbed in transgenic mice since oral galactose induced nearly significant (p = 0.06) increase in this ratio in the rat STZ-icv model (Fig. 9c) , pointing again to the possible species-dependent differences. Therefore, it cannot be excluded that, despite the increment of hippocampal GLP-1R expression in 10M+2M transgenic mice (Fig. 8a) , the lack of plasma GLP-1-mediated effects in Tg2576 mice might have been responsible for the ineffectiveness of oral galactose on cognitive impairment in this transgenic fAD model. This assumption might be supported by the literature indicating the therapeutic potential of GLP-1 analogues, particularly liraglutide, in different transgenic AD mice models (Cai et al., 2018; Cao et al., 2018; Chen et al., 2017; Long-Smith et al., 2013; McClean et al., 2015; McClean and Holscher, 2014; McClean and Hölscher, 2014; Tai et al., 2018b) . However, long-term liraglutide treatment exhibited no effect on cerebral plaque load in two different APP/PS1 mice models representing low-and high-grade amyloidosis, suggesting differential sensitivity in various transgenic mouse models mimicking distinct pathological hallmarks of AD . Additionally, long-term treatment with exenatide, another GLP-1 analogue, promoted beneficial effects on short-and long-term memory performances in PS1-KI but not in 3xTg-AD animals, an effect likely driven by increasing the brain anaerobic glycolysis rate, to which exenatide had no effects in 3xTg-AD mice (Bomba et al., 2013) , pointing again to the significance of the particular model and specific gene pathology as key factors in GLP-1-mediated effects. The combination of traditional transgenic AD mice models with induced insulin impairments in the brain may be a more complete model of AD (Gao et al., 2013; Plaschke et al., 2010) , and it would be worth exploring whether oral galactose would have beneficial effects in such a model.
The effects on glucose metabolism in the brain. Our results of cerebral glucose hypermetabolism observed in the 5M+2M (galactose-untreated) Tg2576 mice are in line with the similar report on FDG-PET assessment in the presymptomatic-staged Tg2576 mice model, where it was proposed to reflect a neuronal compensatory mechanism (Luo et al., 2012) . Indeed, in patients with mild cognitive impairment or mild dementia glucose metabolism in the hippocampus was increased and negatively correlated with the performance in several cognitive subdomains (Apostolova et al., 2018) . Luo and co-workers (Luo et al., 2012) , showed that cerebral glucose hypermetabolism in this particular transgenic fAD model decreases with age, which has been evidenced in average reductions in the cortical region being −17.7% in 10M+2M (galactose-untreated) Tg2576 mice in our work and −20% in > 18 month-old Tg2576 mice in the research of others (Coleman et al., 2017) . Accordingly, brain glucose hypometabolism has been consistently found in AD patients (Alexander et al., 2002; Costantini et al., 2008; Drzezga et al., 2008; Kim et al., 2005) . Since oral galactose-induced normalization of glucose metabolism has not been reflected in the improved cognition in 5M+2M and 10M+2M Tg2576 mice as well as in the STZ rats with mild-to-moderate sAD- (Fig. 9b ) in contrast to the early sAD stage in STZ-icv rat model (Knezovic et al., 2018) , it seems likely that normalization of cerebral glucose metabolism may contribute but is obviously not the major actor in improvement of cognitive deficits in these AD models. Oral galactose could affect cerebral glucose metabolism directly after its intra-neuronal conversion to glucose via the Leloir pathway (Cohn and Segal, 1973) , or indirectly by GLP-1-mediated effects as suggested by literature (Femminella and Edison, 2014) . However, in 12-month-old transgenic mice that express human mutated APP, PS1, and tau proteins, 10-week, liraglutide treatment normalized glucose hypometabolism in forebrain areas in an FDG-PET imaging study which was accompanied by cognitive improvement (Hölscher, 2014c) . It remains to be elucidated to which factor exactly (or their combination) this beneficial effect might be related; GLP-1 analogue, duration of treatment, or particular AD model.
The effects on glucose tolerance and plasma insulin level. Our results corroborated the key role of metabolic changes and indicated that systemic insulin abnormalities occur in Tg2576 mice at the age when the manifestation of cognitive impairment is at its start but not clearly evident yet, indicating a metabolic background for later cognitive impairment progression. Even more so, severe diabetes-like abnormalities in glucose tolerance were evident in cognitively impaired 10M+2M Tg2576 mice. The plasma insulin level in Tg2576 10M+2M mice were decreased to a lesser extent than in the 5M+2M group (−30% vs −50%), and not significantly different compared to the wild-type agematched control, which might be in line with literature data demonstrating that Tg2576 mice become hyperinsulinemic by 13 months of age (Pedersen and Flynn, 2004) . While oral galactose normalized this decrease in the 5M+2M group, in 10M+2M Tg2576 mice not only was this effect missing, but oral galactose treatment tended to cause metabolic exacerbation evident by further decrease in plasma insulin level (−38% in TG + GAL vs. TG mice). These findings corroborate the difference in metabolic background in transgenic fAD and non-transgenic sAD models since at the age of 9 months, plasma insulin levels in STZ-icv rats was not affected by oral galactose treatment and no tendency of its decrement has been observed (Fig. 9c) . However, it could not be excluded that possibly different regulation of species-dependent metabolic response (mice vs. rats) might account for that. In line with GLP-1 acting like an insulin secretagogue, galactose-induced tendency to decrease plasma insulin levels in the control (WT) 10M+2M mice (12-month old at the time of measurement) might result from a similar tendency of decrease observed in their GLP-1 ratio in plasma. The same seems not to apply to the rat controls (9-month old at the time of measurement) in which the tendency to reduce plasma insulin following the galactose treatment is observed in the presence of (insignificantly) increased plasma GLP-1 ratio. In addition to the possible species-related difference, it could not be excluded that age difference in the control mice and rats (12 vs 9 months) could account for different GLP-1 response. Considering the different relating of mice and rats age with the human one (Dutta and Sengupta, 2016; Sengupta, 2013) , age difference might be particularly important in translation of the animalto-human data. Since there are no other literature reports on regulation of GLP-1 and/or insulin secretion after such a long oral galactose treatment in small rodents (or in humans), further research is needed to elucidate this issue.
The effects on the hippocampal IR signaling pathway. Oral galactoseinduced decrease in IR expression and increase in GSK3β activity in the hippocampus of 10M+2M Tg2576 mice could have further detrimental effects downstream IR signaling cascade and contribute to the cognitive impairments in mild fAD-like pathology. Significant galactose-induced decrease in GSK3β activity (reflected from the increased phospho/total GSK3β) ratio in 5M+2M Tg2576 mice might indicate possible beneficial effects at this presymptomatic stage of fAD-like pathology. However, the opposite changes seen in the hippocampus of 9 month old STZ-icv rats (increased IR expression and decreased GSK3β activity) were not affected by oral galactose treatment in this advanced stage of sAD (Fig. 9c) , confirming the difference in the pathophysiology and the metabolic regulation at this level between these fAD and sAD models.
The effects on the hippocampal Aβ levels. Peripheral glucose and insulin metabolism has been implicated in the Aβ precursor protein system, as increased Aβ expression correlates with insulin resistance (Lee et al., 2008; Tharp et al., 2016) . Our results show that metabolic dysfunction can be linked to Aβ metabolism since soluble Aβ1-42 levels were elevated in 5M+2M Tg2576 mice. At the time of sacrifice these mice were at the age of 7 month when amyloid plaques have not been developed yet (Hsiao et al., 1996) , while as the animals become older and develop plaques soluble Aβ1-42 levels decreases as seen here in 10M+2M Tg2576 mice. The increase observed in soluble Aβ1-42 levels in the 10M+2M Tg2576 mice (representing mild fAD stage) may account for the lack of cognition improvement in our cognitive tests since intraperitoneal galactose has been found to increase Aβ levels in galactose-induced brain aging models (Shwe et al., 2018) . Interestingly, oral galactose treatment seems to reduce STZ-icv-induced increase in hippocampal Aβ1-42 levels (Fig. 9c) , although does not normalize cognitive deficit in this mild-to-moderate model of sAD.
Synaptic integrity and function. Our data on unchanged expression of synaptophysin in both age groups of Tg2576 mice compared to their age-matched controls are in line with the literature data of unchanged synaptohysin protein expression in 8-10-month (Spires et al., 2005) and 12-month old (Takeuchi et al., 2000) Tg2576 mice.
However, a different pattern of changes was observed in our experiments with PSD-95, the major scaffold protein of the postsynaptic membrane, which facilitates the anchorage of membrane receptors, modulates trafficking and localization of adhesion molecules, ionchannels and glutamate receptors, and determines the synaptic response (Gong and Lippa, 2010; Savioz et al., 2014) . Human data are more consistent on the variations of PSD-95 expression in brain aging and AD than those in animal AD models (Savioz et al., 2014) . Findings reported in Tg2576 mice model rang from unchanged levels observed in the hippocampus at 3 (D'Amelio et al., 2011) and 8 (Zamarbide et al., 2018) months of age to decreased levels observed in the cerebral cortex at the age of 8-10 months (Spires et al., 2005) , indicating the regionand age-dependent variations. Additionally, possible involvement of PSD-95 in reactive and/or compensatory mechanisms during AD progression seems to be underscored (Savioz et al., 2014) . Our results might support the hypothesis of (Savioz et al., 2014) that in the early disease progression neurons in the hippocampus could react by a compensatory increase in PSD-95 expression (5M+2M mice), but once the reactive stage is over and irreversible disease progression starts to slowly appear, PSD-95 levels would start to fall down first reaching the control values (10M+2M mice) and subsequently further decrease below the control levels, as observed in the hippocampus of 15-monthold Tg2576 mice (Gerenu et al., 2013) . Additionally, possible influence of the prior intensive cognitive activity in our experiments (Morris Water Maze and Passive Avoidance tests) should be taken into account considering the literature data indicating that at the early phase of AD development (similar to that of 5M+2M group), PSD-95 expression might be increased in previously cognitively stimulated Tg2576 mice (6-day Morris Water Maze Test) (Jiang et al., 2015) . It could not be excluded that healthy (wild-type) and transgenic AD mice exhibit different response of PSD-95 expression following the cognitive stimulation since all WT and Tg2576 mice in the experiment were cognitively trained before sacrifice.
Galactose-induced PSD-95 increase in control WT mice compared to the untreated WT group might be related to the finding that following galactose load in rats, there is a time dependent increase of glutamate and GABA in the brain (in contrast to the liver and other peripheral tissues), which persists longer than after similar increase of these neurotransmitters induced by a glucose load (Roser et al., 2009) . Keeping in mind the association of PSD-95 and glutamate receptors, it might be speculated that galactose-induced increase of glutamate would consequently trigger the PSD-95-glutamate receptor interaction and increased PSD-95 expression in 5M+2M wild-type mice. Such a reactive response might be lacking due to the underlying AD pathology in galactose-treated Tg2576 mice (both 5M+2M and 10M+2M groups) but could be also reduced/abolished with aging in wild-type mice (10M +2M).
Conclusion
Two-month oral administration of galactose has no therapeutic potential on cognitive impairment in the 5M+2M and 10M+2M groups of transgenic Tg2576 mice that model the condition of presymptomatic and mild-stage of fAD, respectively. Despite of that, the assessment of the possible mechanisms of oral galactose-induced effects in Tg2576 mice revealed that such a treatment elicits some beneficial effects manifested only in mice representing presymptomatic fAD stage as evidenced by improved reduced grooming behavior and normalization in reduced plasma insulin levels. However, in mice representing the mild fAD stage, oral galactose treatment induced some metabolic exacerbation (relative decrease in plasma active GLP-1 levels and further decrease in plasma insulin) as well as disturbances in hippocampal IR signaling (decreased IR expression and increased GSK3β activity). Oral galactose-induced normalization of disturbances in cerebral glucose metabolism seems unlikely to be a major contributor to cognitive improvement in Tg2576 mice. The lack of stimulation of the activity of the endogenous plasma GLP-1 might be considered as a possible key factor, which disabled cognitive improvement in oral galactose-treated Tg2576 mice. This is supported by our previous findings of oral galactose-induced cognitive improvement in an early-staged sAD represented by STZ-icv rats, associated with normalization of reduced plasma active GLP-1 levels and increased hippocampal expression of GLP-1 receptors. Contrary to that, no cognitive improvement was associated with the decreased GLP-1 receptor expression observed here in STZ-icv rats with mild-to-moderate sAD. Our results suggest that possible therapeutic potential of oral galactose in experimental AD condition seems to depend on the specific underlying AD pathology, in particular the sporadic or familial form (or the model) and the stage of AD pathological hallmarks. Additionally, our results suggest that it differs in the absence (healthy controls) and the presence of AD-like pathology, and that possible age-and species-related difference in metabolic regulation and consequent response to the therapy should be further explored. The results presented here provide novel findings on the metabolic characterization of the Tg2576 mice AD model and its response to oral galactose treatment, which have an important translational value in transgenic mice-to-human research and should be considered in further research of the therapeutic potential of this nutrient in general.
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